Psychiatry Research最新文献

{"title":"The role of astrocytes in attention-deficit hyperactivity disorder: An update","authors":"Louisa Charlotte Dury ,&nbsp;Cristine Marie Yde Ohki ,&nbsp;Klaus-Peter Lesch ,&nbsp;Susanne Walitza ,&nbsp;Edna Grünblatt","doi":"10.1016/j.psychres.2025.116558","DOIUrl":"10.1016/j.psychres.2025.116558","url":null,"abstract":"<div><div>Attention-deficit hyperactivity disorder (ADHD), the most prevalent neurodevelopmental disorder, is characterized by inattention, hyperactivity, and impulsivity, manifesting in distinct symptoms and varying degrees of severity among patients. While the cellular processes underlying the neurobiology of ADHD are still being explored, <em>in vitro</em> studies suggest the involvement of certain cellular pathways in its clinical manifestations.</div><div>Neurodevelopmental disorders such as ADHD are caused by malfunctions in numerous cells in the central nervous system (CNS) throughout development; nevertheless, most of the research focuses on neuronal dysfunction. In the last decade, it has become evident that glia and astrocytes play a crucial role in neurodevelopmental processes, which, if deficient, may result in neurodevelopmental disorders.</div><div>Besides contributing to homeostatic maintenance of the blood-brain barrier (BBB) and other glial cell types, astrocytes provide neurons with structural, trophic, and metabolic support, which is indispensable for their proper functionality. Emerging evidence implicates that astrocytes are involved in processes associated with the etiopathology of ADHD, including oxidative stress, aberrant synaptic formation, neuroinflammation, and excitatory/inhibitory imbalance.</div><div>This review will summarize the current knowledge addressing astrocyte dysfunction in ADHD, the remaining caveats in clinical data, and the possibilities for drug therapy. Findings substantiated by <em>in vivo, in vitro</em>, and genetic data will be provided, along with the impact of methylphenidate on astrocyte condition.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116558"},"PeriodicalIF":4.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Development and psychometric evaluation of the Man-Made Disaster-Related Distress Scale (MMDS)”, Psychiatry Research 324 (2023) 115193","authors":"J.B. Krakowczyk ,&nbsp;J. Beckord ,&nbsp;J. Planert ,&nbsp;P. Kohl ,&nbsp;A. Schweda ,&nbsp;M. Teufel ,&nbsp;A. Bäuerle","doi":"10.1016/j.psychres.2025.116556","DOIUrl":"10.1016/j.psychres.2025.116556","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116556"},"PeriodicalIF":4.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of dose on early treatment response to bifrontal electroconvulsive therapy in Schizophrenia: A retrospective study","authors":"Birong Chen,&nbsp;Xiao Wei Tan,&nbsp;Phern Chern Tor","doi":"10.1016/j.psychres.2025.116554","DOIUrl":"10.1016/j.psychres.2025.116554","url":null,"abstract":"<div><div>Schizophrenia is the leading indication for electroconvulsive therapy (ECT) in Asia; however, optimal ECT parameters for this condition remain under-researched. This study examines the impact of stimulus dosage in bifrontal ECT on symptomatic improvement in 122 patients treated at the Institute of Mental Health, Singapore.</div><div>In this retrospective analysis, patients were categorized into two groups based on a 1.5 × seizure threshold (DRST) cutoff: a standard dosage group (≤1.5 × DRST) and a high dosage group (&gt;1.5 × DRST). Paired <em>t</em>-tests were used to assess changes in clinical scores—positive psychotic symptoms, quality of life, and cognition—after six ECT sessions. Generalized linear models evaluated associations between dosage groups and symptomatic changes.</div><div>Both groups showed significant improvements in positive psychotic symptoms, as measured by the Brief Psychiatric Rating Scale (BPRS) positive psychotic symptom subscale (<em>p</em> &lt; 0.001), and in quality of life (Q-LES-Q-SF and EQ-5D utility scores; <em>p</em> &lt; 0.03 for the high-dose group, <em>p</em> = 0.006 for the standard-dose group). Only the standard dosage group demonstrated significant cognitive improvement (MoCA, <em>p</em> = 0.04), while the high-dose group did not. Notably, the high-dose group experienced greater reductions in positive psychotic symptom scores (<em>p</em> = 0.004) and greater improvements in quality of life (<em>p</em> = 0.002) compared to the standard-dose group. However, linear regression analysis found no significant between-group differences in post-treatment MoCA scores.</div><div>These findings suggest that higher suprathreshold dosages of bifrontal ECT may accelerate improvement in positive psychotic symptoms in schizophrenia, highlighting the need for further research to optimize ECT protocols and treatment outcomes.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116554"},"PeriodicalIF":4.2,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot randomized controlled trial of a digital cannabis harm reduction intervention for young adults with first-episode psychosis who use cannabis","authors":"Stephanie Coronado-Montoya ,&nbsp;Amal Abdel-Baki ,&nbsp;Paule Bodson-Clermont ,&nbsp;David Boucher-Roy ,&nbsp;José Côté ,&nbsp;Candice E. Crocker ,&nbsp;David Crockford ,&nbsp;Jean-Gabriel Daneault ,&nbsp;Simon Dubreucq ,&nbsp;Maxime Dussault-Laurendeau ,&nbsp;Benedikt Fischer ,&nbsp;Pamela Lachance-Touchette ,&nbsp;Tania Lecomte ,&nbsp;Sophie L’Heureux ,&nbsp;Clairélaine Ouellet-Plamondon ,&nbsp;Marc-André Roy ,&nbsp;Ovidiu Tatar ,&nbsp;Philip G Tibbo ,&nbsp;Marie Villeneuve ,&nbsp;Anne Wittevrongel ,&nbsp;Didier Jutras-Aswad","doi":"10.1016/j.psychres.2025.116553","DOIUrl":"10.1016/j.psychres.2025.116553","url":null,"abstract":"<div><div>Cannabis use is widespread and associated with worsened prognosis for young adults with first-episode psychosis (FEP). Few cannabis harm reduction interventions have been evaluated for this population, despite potential to improve outcomes in those not ready for cannabis abstinence/reduction-focused interventions. This study aimed to determine a) the acceptability of a digital harm reduction intervention, the Cannabis Harm-reducing App to Manage Practices Safely (CHAMPS) and b) the feasibility of conducting a trial comparing FEP-specialized early intervention services (EIS)+CHAMPS versus EIS-only with this population. We conducted a multi-site pilot randomized controlled trial comparing both arms in 101 young adults (18 - 35 years old) with FEP using cannabis and attending EIS. Primary outcomes were trial retention rate (i.e., proportion of randomized participants retained at week 6; trial feasibility assessment) and CHAMPS completion rate (i.e., proportion of intervention participants completing four of six modules; CHAMPS acceptability assessment). Trial retention rate above 60 % indicated feasibility and completion rate above 50 % indicated acceptability. Additional outcomes included harm reduction strategy use, motivation to change cannabis behaviors, cannabis-related problems, cannabis use, psychotic symptoms and dependence severity, assessed at baseline, weeks 6, 12 and 18. Trial retention was 82.2 % and completion rate was 58.8 %, suggesting trial feasibility and CHAMPS acceptability. Signals of possible improvement in the intervention group were observed regarding harm reduction strategy use, motivation to change behaviors, cannabis-related problems and cannabis use frequency. This study supports conducting an efficacy trial assessing the potential of CHAMPS in improving outcomes for young adults with psychosis using cannabis.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116553"},"PeriodicalIF":4.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal cannabis in the management of anxiety disorders: A systematic review","authors":"Leah Roberts ,&nbsp;Elizabeth Sorial ,&nbsp;Charley A. Budgeon ,&nbsp;Kenneth Lee ,&nbsp;David B. Preen ,&nbsp;Craig Cumming","doi":"10.1016/j.psychres.2025.116552","DOIUrl":"10.1016/j.psychres.2025.116552","url":null,"abstract":"<div><h3>Background</h3><div>With rising anxiety disorder diagnoses, many individuals are seeking alternatives to standard pharmacotherapies, like medicinal cannabis. This systematic review focuses exclusively on anxiety-related disorders and examines a wide range of cannabis-based preparations and interventions.</div></div><div><h3>Method</h3><div>We searched MEDLINE, EMBASE, CINAHL, and PsycInfo (October–December 2023) for peer-reviewed empirical studies, excluding case series, case studies, and review papers. Inclusion criteria were studies on adults (18+ years) diagnosed with anxiety-related disorders, examining the efficacy or effectiveness of medicinal cannabis. Studies on recreational cannabis or cannabis-use-disorder were excluded. The MASTER and QualSyst tools were used to assess bias.</div></div><div><h3>Results</h3><div>Fifty-seven studies met the inclusion criteria: 40 % cohort (<em>n</em> = 23), 30 % randomised controlled trials (<em>n</em> = 17), 18 % cross-sectional (<em>n</em> = 10), 12 % qualitative or other designs (<em>n</em> = 7). The MASTER scale revealed a high risk of bias, with a mean score of 62.9 (out of 100) due to inadequate reporting. Among the 13 highest-quality studies, 70 % (<em>n</em> = 9) reported a positive improvement for disorders including generalised anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). 30 % (<em>n</em> = 4) reported a negative result for conditions like obsessive-compulsive disorder, trichotillomania, test anxiety and SAD. Over 90 % of all studies, including lower quality studies, reported positive outcomes for CBD and THC-based cannabis. However, 53 % (<em>n</em> = 30) either omitted, or included self-reported data on either form and/or dosage.</div></div><div><h3>Conclusion</h3><div>Medicinal cannabis demonstrates potential in reducing anxiety symptoms, but the long-term benefits and overall impact on quality of life remain unclear. Further high-quality, longitudinal research with standardised dosing is needed.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116552"},"PeriodicalIF":4.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From resting-state functional hippocampal centrality to functional outcome: An extended neurocognitive model of psychosis","authors":"Jana F. Totzek ,&nbsp;Jai L. Shah ,&nbsp;Alexandra L. Young ,&nbsp;Ashok Malla ,&nbsp;Ridha Joober ,&nbsp;Delphine Raucher-Chéné ,&nbsp;Martin Lepage ,&nbsp;Katie M. Lavigne","doi":"10.1016/j.psychres.2025.116538","DOIUrl":"10.1016/j.psychres.2025.116538","url":null,"abstract":"<div><h3>Background</h3><div>We previously proposed a neurocognitive model of psychosis in which reduced morphometric hippocampal-cortical connectivity precedes impaired episodic memory, social cognition, negative symptoms, and functional outcome. We provided support for this model in a patient subtype, and aimed to extend these findings to resting-state functional MRI to potentially explain the progression for a broader range of patients.</div></div><div><h3>Methods</h3><div>We used a subsample of our previous analysis consisting of 54 patients with first-episode psychosis and 52 controls and applied the machine-learning algorithm Subtype and Stage Inference, which combines clustering and disease progression modeling, to the patient data for rs-functional hippocampal connectivity, episodic memory, social cognition, negative symptoms and functioning.</div></div><div><h3>Results</h3><div>We identified three subtypes, with Subtype 0 being unimpaired on the markers, Subtype 1 showing impaired hippocampal connectivity and episodic memory, and Subtype 2 showing impaired memory and a trend for impaired functioning. We identified similar progression patterns to our previously published morphometric results in functional MRI data (hippocampal dysconnectivity preceded cognition, symptoms, and functioning in one subtype and followed these alterations in another subtype). We further show that the impairments in our previously published and current findings across modalities do not necessarily overlap in patients, hinting towards an additive effect of morphometric and resting-state connectivity in explaining the neurocognitive underpinnings of this model.</div></div><div><h3>Conclusion</h3><div>Our results provide an extension of our previous work and build the foundation for a multimodal neurocognitive model of psychosis, potentially elucidating this aspect of illness progression in psychosis for a broader range of patients.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116538"},"PeriodicalIF":4.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Antipsychotic discontinuation in nonaffective first-episode psychosis after clinical remission: Insights from the PEPsNa naturalistic study’ [ Psychiatry Research volume 342 (December 2024) 1–10/116261]","authors":"Gerardo Gutierrez ,&nbsp;Elena Garcia de Jalon ,&nbsp;Lidia Aranguren ,&nbsp;Asier Corrales ,&nbsp;Gustavo J. Gil-Berrozpe ,&nbsp;Ana M. Sánchez-Torres ,&nbsp;Julian Librero ,&nbsp;Victor Peralta ,&nbsp;Manuel J. Cuesta ,&nbsp;PEPsNa group","doi":"10.1016/j.psychres.2025.116539","DOIUrl":"10.1016/j.psychres.2025.116539","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116539"},"PeriodicalIF":4.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health anxiety and somatic symptoms in adults on the autism spectrum","authors":"Wei-Lieh Huang ,&nbsp;Bennett Leventhal ,&nbsp;Chao-Cheng Lin ,&nbsp;Yi-Ling Chien","doi":"10.1016/j.psychres.2025.116550","DOIUrl":"10.1016/j.psychres.2025.116550","url":null,"abstract":"<div><h3>Background</h3><div>Somatic symptoms and health anxiety impact quality of life. Whether somatic symptoms and health anxiety correlate with autistic traits, anxiety/depression, sensory and personality characteristics has yet to be systematically investigated among autistic people. This study aimed to investigate somatic symptoms and health anxiety in autistic, and their clinical correlates.</div></div><div><h3>Methods</h3><div>This study recruited 221 autistic adults (aged 28.1±8.5), 514 somatic symptom disorder (SSD), 194 anxiety or depressive disorders (affective disorder group, AFD), and 555 non-autistic controls. All participants completed the Health Anxiety Questionnaire and Patient Health Questionnaire-15 scales to assess health anxiety and somatic symptoms.</div></div><div><h3>Results</h3><div>Autistic adults showed greater somatic symptoms and health anxiety than non-autistic controls. The level was similar to the AFD but lower than the SSD groups. Harm avoidance and low registration were associated with health anxiety and somatic symptoms in autism, while attention to details was positively associated with the needs of reassurance. Health-related anxiety was related to both depression and anxiety, and most domains on quality of life, with excessive health-related worries associated with greater anxiety and lower environmental life quality.</div></div><div><h3>Conclusion</h3><div>Findings suggest significant somatic symptoms and health anxiety in autistic adults that warrants clinical attention.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116550"},"PeriodicalIF":4.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bias against psychotic experiences in peer review","authors":"Zui C Narita","doi":"10.1016/j.psychres.2025.116549","DOIUrl":"10.1016/j.psychres.2025.116549","url":null,"abstract":"","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116549"},"PeriodicalIF":4.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The decision to help-seek within 24-hours following a suicide attempt: Rate and proximal correlates within an emergency department sample","authors":"Anne C. Knorr ,&nbsp;Brooke A. Ammerman ,&nbsp;Nathan A. Hoff ,&nbsp;Laura Congelio ,&nbsp;Kassidy Unger ,&nbsp;Robert Strony","doi":"10.1016/j.psychres.2025.116541","DOIUrl":"10.1016/j.psychres.2025.116541","url":null,"abstract":"<div><div>There is a critical need to identify proximal factors associated with help-seeking following a suicide attempt (SA; i.e., attempt to kill oneself). Many individuals receive emergency department care following a SA; however, little is known about factors distinguishing individuals who present to the emergency department voluntarily (i.e., played an active role in presentation through their own action to obtain help or through requesting help) and those who do not (i.e., brought to the emergency department due to no action of their own) following a SA, which could improve suicide prevention efforts. It was hypothesized that using a poisoning SA method and experiencing social support would increase the likelihood of help-seeking following SA. This study utilized electronic health record data for 553 emergency department patients (<em>M</em>_age = 37.94 [<em>SD</em> = 15.67], 53.30 % female, 94.40 % white) presenting within 24-hours after SA during a two and a half year period across six hospitals within a rural healthcare system. Within 24-hours of SA, 34.4 % engaged in help-seeking. The use of a poisoning SA method and a diagnosis of borderline personality disorder increased the likelihood of help-seeking, whereas a diagnosis of bipolar disorder and being in a romantic relationship decreased the likelihood. Results can inform suicide prevention initiatives to promote help-seeking immediately following SA, a critical period that may represent the last opportunity for self-intervention prior to the occurrence of lasting serious injury or death by suicide.</div></div>","PeriodicalId":20819,"journal":{"name":"Psychiatry Research","volume":"350 ","pages":"Article 116541"},"PeriodicalIF":4.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}